Thymoquinone modifies CD4+:CD8+ ratio without affecting tumor necrosis factor-α and interleukin-1β levels in Wallerian degeneration crush injury rat model

• Published in: Neuroscience and behavioral physiology 2024, Vol.54 (1), p.1-9
• Main Authors: Besin, Valentinus, Bajamal, Abdul Hafid, Nugraha, Jusak, Notopuro, Paulus Budiono, Naesilla, Naesilla, Humardani, Farizky Martriano
• Format: Article
• Language: English
• Subjects: Animal models; Behavioral Sciences; Biomedical and Life Sciences; Biomedicine; CD4 antigen; CD8 antigen; Enzyme-linked immunosorbent assay; Flow cytometry; IL-1β; Inflammation; Lymphocytes T; Neurobiology; Neurodegeneration; Neurosciences; Peripheral blood; Placebos; Regeneration; Sciatic nerve; Statistical analysis; Tumor necrosis factor-TNF; Tumor necrosis factor-α
• ISSN: 0097-0549; 1573-899X
• DOI: 10.1007/s11055-023-01523-4

Wallerian degeneration following nerve injury not only suppresses CD4+ T-cell responses but also promotes pro-inflammatory immunological responses through TNF-α and IL-1β. Recent research suggests that thymoquinone might enhance nerve recovery by exerting anti-inflammatory effects on both the innate and adaptive immune systems. This study aims to evaluate the effect of thymoquinone on neuroinflammation in a sciatic nerve crush injury, as represented by TNF-α, IL-1β, and the CD4+:CD8+ ratio. In this study, 126 crush injury Wistar rats were divided into three main groups: placebo, thymoquinone 100 mg/kg, and thymoquinone 250 mg/kg administered daily. Rats were euthanized at six distinct time points: 12, 18, and 24 hours, as well as on day-5, day-6, and day-7. TNF-α and IL-1β levels were assessed using the Enzyme-Linked Immunosorbent Assay (ELISA). The CD4+:CD8+ ratio in peripheral blood was determined via flow cytometry. No significant TNF-α differences was found between treatment and placebo groups. However, on day 6, IL-1β was significantly lower in the TQ 250mg/kg group than in the placebo (p=0.008). A similar but non-significant trend existed on days 6 and 7. On day 5, both TQ groups showed a higher, statistically significant CD4+:CD8+ ratio compared to placebo (p=0.007), a trend that continued to day 7 but not statistically significant. Daily TQ administration did not consistently reduce TNF-α and IL-1ß levels. However, both doses elevated the CD4+:CD8+ ratio during the early stages of Wallerian degeneration, suggesting a potential benefit of TQ on nerve regeneration.